Japanese Pharmas Need To Get More Global
This article was originally published in PharmAsia News
Japanese pharmaceutical companies need to have a more global reach if they intend to be major players in an increasingly international biotech and pharma market, according to Berkeley, Calif.-based Plexxikon CEO Peter Hirth
You may also be interested in...
Plexxikon’s PLX-4032 could eventually compete against biologics in the colorectal cancer market.
CEO Taurel argues in favor of an open market that would ease Japan-specific clinical trial requirements.
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).